in an orthotopic mouse model. One week of treatment of tumour-bearing immunocompromised RIP1-Tag2 mice with the anti-VEGFR2 antibody DC101 resulted in significantly more invasive tumours ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...